Finzati - Logo
ZTS logo

Zoetis Inc.

ZTS • Drug Manufacturers - General
$75.81
▼ -0.48 (-0.63%)
Current price
EarningsLatest report: Jun 30, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$32.38B
Growth
8.5%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 28.2%Positive revenue growth · 6.8%Positive free cash flow · 5.15Consistent free cash flow · 5/5Reasonable earnings multiple · 20.87
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 12:18 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$75.81
Change-0.63%
Market Cap$32.38B
52W Range71.47 - 160.48
Beta0.75
Gross Margin70.49%
Oper. Margin38.00%
Profit Margin28.23%
Debt/Eq2.85
Current Ratio3.03
Quick Ratio1.94
Revenue 5Y8.52%

Investment DNA

How strong this company looks for long-term investors

81
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
82/100
Price Attractiveness
Cheap or expensive today
53/100
Why this score▼
Stable or improving margins · 28.2%Positive revenue growth · 6.8%Positive free cash flow · 5.15Consistent free cash flow · 5/5Reasonable earnings multiple · 20.87Healthy liquidity · 3.03

Analyst view

Analyst sentiment and price target

Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-08-07
Low
$85.00
Mean
$101.50
Median
$90.00
High
$160.00

Company Overview

IPO: 2/1/2013
Industry: Drug Manufacturers - General
P/B i: 16.75
Debt / Equity i: 2.85
Operating Margin: 38.00%
Net Margin: 28.23%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 2.85
Current Ratio: 3.03
Quick Ratio: 1.94
Status: Good

Warnings

  • High debt level

Insider Transactions

Recent executive and insider activity

Joseph Wetteny
Transaction: 07/10/2026
BUY
Change
—
Price
Not reported
Filing
07/14/2026
Type
BUY
Ferran Astorga Jeannette
Transaction: 07/10/2026
BUY
Change
—
Price
Not reported
Filing
07/14/2026
Type
BUY
Lagano Roxanne
Transaction: 07/10/2026
BUY
Change
—
Price
Not reported
Filing
07/14/2026
Type
BUY